695 Efficacy and safety of trastuzumab deruxtecan (T-DXd) with durvalumab in patients with non-small cell lung cancer (HER2 altered NSCLC) who progressed on anti-PD1/PD-L1 therapy (HUDSON)

Authors :: Rakesh Kumar
Keunchil Park
Frances A Shepherd
John V Heymach
Quincy Chu
Sylvia Hartl
J Carl Barrett
Sonia Iyer
Parneet Cheema
Marianna Koczywas
Maximilian Hochmair
Giuseppe Galletti
Mark Gustavson
Brent Evans
Jan Cosaert
Source :: Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Publication Year :: 2023
Publisher :: BMJ Publishing Group, 2023.

Subjects :: Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282

Full Text Access

Tools